PANNEXIN Pannexin 1 – a novel target for pediatric orphan epilepsy
- Coordinator
- Panntherapi, France
- Runs
- 1 October 2023 to 31 March 2026
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €4.1m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190121670
What the project is doing
In the project's own words, from its summary on CORDIS.
Epilepsy is a group of syndromes with high unmet medical need, especially in children as frequent seizures affect the immature brain and its development. In some orphan syndromes, drug resistance is 70% with dramatic consequences for patients and their families. Novel treatments must prevent the negative effects of seizures, but also minimize off-target effects on brain development and cognitive functions. Our solution is the specific blockade of the activated form of the Pannexin 1 (Panx1) channel using a reformulated form of probenecid: PTI5803.
This compound, a first-in-class drug, inhibits seizures preclinically in >80% of cases without hampering cognitive functions. Designed to be adapted to children (from 6 months of age) and to improve the bioavailability, PTI5803 is a highly specific breakthrough product to counteract the pathological activation of Panx1 in patients with an ultra-resistant orphan epilepsy, with the potential to disrupt the market of paediatric epilepsy.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Panntherapi | Nimes | France | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI